Published in J Urol on December 01, 2005
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol (2007) 1.05
Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values. J Natl Compr Canc Netw (2010) 0.84
Perioperative and continence outcomes of robotic radical prostatectomy in elderly Indian men (≥70 years): A sub-group analysis. Indian J Urol (2015) 0.79
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet (2009) 5.06
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol (2004) 4.41
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Delay of surgery in men with low risk prostate cancer. J Urol (2011) 3.05
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
Combination of Foley bulb and vaginal misoprostol compared with vaginal misoprostol alone for cervical ripening and labor induction: a randomized controlled trial. Obstet Gynecol (2013) 2.67
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol (2010) 2.49
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol (2010) 2.35
The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Serial biopsy results in prostate cancer screening study. J Urol (2002) 2.30
A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet (2012) 2.29
National trends in the utilization of partial nephrectomy before and after the establishment of AUA guidelines for the management of renal masses. Urology (2013) 2.28
Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst (2003) 2.26
Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst (2013) 2.20
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol (2004) 2.15
Interval from loop electrosurgical excision procedure to pregnancy and pregnancy outcomes. Obstet Gynecol (2013) 2.15
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Terminal fetal heart decelerations and neonatal outcomes. Obstet Gynecol (2013) 2.05
Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol (2013) 2.01
Association of hemospermia with prostate cancer. J Urol (2004) 1.98
Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol (2005) 1.98
Normal progress of induced labor. Obstet Gynecol (2012) 1.93
Natural history of placenta previa in twins. Obstet Gynecol (2012) 1.93
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol (2007) 1.90
Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem (2004) 1.85
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol (2009) 1.77
Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. J Urol (2007) 1.77
Single umbilical artery and its associated findings. Obstet Gynecol (2010) 1.76
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer (2007) 1.70
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int (2012) 1.68
Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res (2014) 1.65
Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology (2010) 1.64
Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol (2010) 1.64
What to do with an abnormal PSA test. Oncologist (2008) 1.62
Prostate specific antigen testing among the elderly--when to stop? J Urol (2009) 1.62
Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols. Urology (2009) 1.62
Under diagnosis and over diagnosis of prostate cancer. J Urol (2007) 1.61
Congenital uterine anomalies and adverse pregnancy outcomes. Am J Obstet Gynecol (2011) 1.60
Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology (2013) 1.57
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology (2006) 1.51
Association of atypical decelerations with acidemia. Obstet Gynecol (2012) 1.50
Prostate cancer diagnosis is associated with an increased risk of erectile dysfunction after prostate biopsy. BJU Int (2012) 1.47
Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol (2008) 1.46
Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet (2006) 1.46
Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer (2008) 1.46
Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol (2011) 1.45
Biomarkers for prostate cancer. Annu Rev Med (2009) 1.45
Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum Genet (2007) 1.45
Prostate-specific antigen in clinical practice. Cancer Lett (2007) 1.44
Lymphovascular invasion in radical prostatectomy specimens: prediction of adverse pathologic features and biochemical progression. Urology (2006) 1.44
PSA enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness. Prostate (2013) 1.43
Impact of fetal gender on the labor curve. Am J Obstet Gynecol (2012) 1.42
Prostate-cancer screening. N Engl J Med (2009) 1.42